Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | RNF4 | P78317 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.58 |
| ▸ | GCK | P35557 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053559 | 0.89 | CA12 (0.73) | HPGDSMN1; SMN2PGRMAPK1CA12 | |
| SCHEMBL12362185 | 0.87 | ALDH1A1 (0.56) | HPGDSMN1; SMN2MAPK1NPC1RAB9A | |
| SCHEMBL21295380 | 0.87 | CA12 (0.71) | HPGDSMN1; SMN2PGRMAPK1CA12 | |
| SCHEMBL11828386 | 0.86 | MMP13 (0.59) | HPGDSMN1; SMN2MAPK1NPC1RAB9A | |
| SCHEMBL11837483 | 0.86 | KMT2A (0.59) | SMN1; SMN2MAPK1CA1CA2CA9 | |
| SCHEMBL11211518 | 0.85 | MEN1 (0.60) | HPGDSMN1; SMN2MAPK1CA12CA1 | |
| SCHEMBL11338762 | 0.85 | GPR174 (0.56) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL11838623 | 0.84 | ALDH1A1 (0.79) | SMN1; SMN2MAPK1CA12CA1CA2 | |
| SCHEMBL21295574 | 0.84 | NPC1 (0.76) | HPGDSMN1; SMN2PGRMAPK1CA12 | |
| SCHEMBL12994776 | 0.84 | HPGD (0.65) | HPGDSMN1; SMN2PGRMAPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| US-9187470-B2 | Anti-mucus drugs and uses therefor | WASHINGTON UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| EP-0777471-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996003983-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| US-3933814-A | ANTIPROTOZOA, ANTICOCCIDIOSIS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | MAPK13, MAPK11, MUC1 | HPGD 113/4885SMN1; SMN2 4868/4885PGR 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.